Latest Regulatory News

Regal Investment Fund has announced an estimated ordinary dividend of AUD 0.12 per unit for the half-year ending December 2025, alongside a full Dividend Reinvestment Plan available to eligible investors.

Seven West Media shareholders convened on 22 December 2025 to vote on a landmark acquisition by Southern Cross Media Group, potentially reshaping Australia's media landscape. The proposed scheme promises a combined media powerhouse spanning television, digital, audio, and publishing.

Neuren Pharmaceuticals has secured Health Canada approval to expand its pivotal Phase 3 trial of NNZ-2591 for Phelan-McDermid syndrome into Canadian sites, complementing ongoing US enrolment.

The Northern Finland Administrative Court has overturned Kingsrose Mining’s exploration permit for the Penikat Project due to procedural errors by the regulator, delaying planned drilling until at least April 2026. Kingsrose remains confident in the project’s long-term potential despite the setback.

Beetaloo Energy’s Carpentaria-5H well has delivered one of the highest gas flow rates in the Beetaloo Basin, showcasing promising long-term productivity and paving the way for pilot gas sales in 2026.

Viridis Mining and Minerals has achieved a critical environmental milestone with the granting of the Preliminary License for its Colossus Rare Earth Project in Brazil, significantly de-risking the development timeline and paving the way for construction in 2026.

Midas Minerals has completed its acquisition of the Otavi Copper Project in Namibia, initiating multiple drilling programs across high-grade deposits and securing strong funding to drive exploration in 2026.

Regis Healthcare announces the resignation of CEO Dr Linda Mellors after six years, with a transition period underway as the board searches for her successor.

Comet Ridge Limited has obtained federal environmental approval for its Mahalo North natural gas project, paving the way for expanded development in Queensland’s Bowen Basin. This milestone complements recent ownership consolidation and state approvals, positioning the company to boost east coast gas supply.

Cann Group Limited has launched a comprehensive suite of option offers aimed at raising incremental capital, subject to shareholder approval at a December 23 meeting. The prospectus outlines potential dilution and financial impacts as the company seeks to strengthen its balance sheet.

Cyclopharm Limited has secured regulatory approval for its Technegas lung imaging technology in Colombia, marking its presence in 67 countries worldwide. This milestone aligns strategically with the upcoming global nuclear medicine congress in Cartagena.

Clarity Pharmaceuticals has secured positive FDA guidance to initiate a pivotal Phase III trial of its Cu-64 SARTATE diagnostic agent for neuroendocrine tumours, aiming to improve detection and patient outcomes.